We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Study Discovers Breast Cancer Metastasis Gene

Study Discovers Breast Cancer Metastasis Gene

Study Discovers Breast Cancer Metastasis Gene

Study Discovers Breast Cancer Metastasis Gene

Read time:

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Study Discovers Breast Cancer Metastasis Gene"

First Name*
Last Name*
Email Address*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Monash researchers have discovered an entirely new gene, responsible for triggering breast cancer, increasing tumour growth and regulating metastasis (the spreading of tumours throughout the body), which is the main killer in most cases of the disease.

The research team, headed by Professor Christina Mitchell from the Department of Biochemistry and Molecular Biology, uncovered the gene, called proline-rich inositol polyphosphate 5-phosphatase, or PIPP.

"The discovery of the new tumour suppressor could have significant implications for the way we treat, manage and even potentially detect specific subsets of breast cancers that need targeted or specific treatments related to the gene expression profile in which PIPP expression is lost," Professor Mitchell said.

Dr Lisa Ooms, the lead author of the paper, said PIPP plays a major role in the initiation and growth of the primary tumour. Together with another already-known oncogene, AKT1, it is implicated in the spread of the disease – the leading cause of breast cancer death, she explained.

The research has three major implications.

The first is that it may help identify a subset of patients that could be targeted with therapies aimed at PIPP and the oncogene pathway PIPP regulates.

Secondly, it may assist in identifying patients at risk of developing secondary cancer, allowing clinicians to make better-informed decisions on whether to implement aggressive or targeted therapy.

Thirdly, the findings could open the way to developing a potential drug that to target the primary cancer and prevent or slow its growth.

Breast cancer is the most common cancer in women, with around 42 Australians diagnosed each day. Once it has spread, chemotherapy is the only option for treatment, and the chances for a complete cure are reduced.